MedMira Inc. (TSXV:MIR)

Canada flag Canada · Delayed Price · Currency is CAD
0.120
0.00 (0.00%)
Feb 21, 2025, 3:53 PM EST
20.00%
Market Cap 84.21M
Revenue (ttm) 356.43K
Net Income (ttm) -3.85M
Shares Out 701.73M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,077
Average Volume 54,074
Open 0.120
Previous Close 0.120
Day's Range 0.115 - 0.120
52-Week Range 0.070 - 0.140
Beta 10.21
RSI 45.31
Earnings Date Apr 2, 2025

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screenin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 52
Stock Exchange TSX Venture Exchange
Ticker Symbol MIR
Full Company Profile

Financial Performance

In 2024, MedMira's revenue was 412,568, a decrease of -4.61% compared to the previous year's 432,529. Losses were -3.33 million, 24.3% more than in 2023.

Financial Statements

News

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clin...

4 weeks ago - Accesswire

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its...

4 weeks ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal®...

5 weeks ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Re...

5 weeks ago - Accesswire

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial...

6 weeks ago - Accesswire

MedMira Reports First Quarter Results FY2025

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, Med...

7 weeks ago - Accesswire

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rap...

2 months ago - Accesswire

MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023,...

3 months ago - Accesswire

MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vic...

5 months ago - Accesswire

MedMira Reports Third Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focuse...

8 months ago - Accesswire

MedMira Announces the Hire of Vice President of Business Development

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of ...

10 months ago - Accesswire

MedMira Reports Second Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira...

11 months ago - Accesswire

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s...

1 year ago - Accesswire

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products

Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canad...

1 year ago - Accesswire

Corporate Update on Clinical Evaluation of MedMira's Products

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required sub...

1 year ago - Accesswire

MedMira Reports First Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, Med...

1 year ago - Accesswire

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Ra...

1 year ago - Accesswire

MedMira Reports FY2023 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2023. Corporate Update Throughout the re...

1 year ago - Accesswire

Update on MedMira's Regulatory Path in Canada and the USA

HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious dise...

1 year ago - Accesswire

MedMira Reports Third Quarter Results FY2023

HALIFAX, NS / ACCESSWIRE / June 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2023. Corporate Update Summary During the third fi...

1 year ago - Accesswire

MedMira Reports Second Quarter Results FY2023

HALIFAX, NS / ACCESSWIRE / April 3, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2023. Corporate Update Summary During the second...

2 years ago - Accesswire

MedMira Enters into Partnership with Maternova for USA and Latin America

HALIFAX, NS / ACCESSWIRE / February 20, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the singing of a multinational distribution agreement with ​Maternova, Inc. , Rhode Island, USA. ​Mate...

2 years ago - Accesswire

Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis

PROVIDENCE, R.I. & HALIFAX, Nova Scotia--(BUSINESS WIRE)-- #HIV--Maternova gains distribution rights across the U.S. and Latin America for MedMira's rapid diagnostics for sexually transmitted diseases...

2 years ago - Business Wire

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

HALIFAX, NS / ACCESSWIRE / January 11, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination ...

2 years ago - Accesswire

Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

HALIFAX, NS / ACCESSWIRE / January 3, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sex...

2 years ago - Accesswire